A phase 1, first-in-human study of Guselkumab (an IL-23-specific mAb) to demonstrate clinical and molecular response in patients with moderate-to-severe psoriasis.
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2014
Price : $35 *
At a glance
- Drugs Guselkumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- 22 Apr 2014 New trial record
- 01 Apr 2014 Results published in the Journal of Allergy and Clinical Immunology.